The principal objective of the Geisinger Clinical Oncology Program is to enroll a maximum number of participants onto NCI-approved cancer prevention, cancer control and cancer treatment protocols, bringing research-quality cancer care to a large rural population of Pennsylvania. The Geisinger Health System serves more than 2.3 million Pennsylvanians across 31 primarily rural counties in the central and northeastern parts of the state. This Health System includes a 535 physician primary and multispecialty group practice in 45 sites, anchored by the 437 bed tertiary care Geisinger Medical Center in Danville, the largest rural tertiary center in the U.S. The other major hubs of the System are in State College (90-member multispecialty group) and Wilkes-Barre (160 bed hospital with 100-member multispecialty group). These hubs will each be an important CCOP site as well. Geisinger Health system operates a staff model HMO with nearly 300,000 members that works cooperatively with the CCOP to promote cancer prevention trials. Among Geisinger's advantages are a stable and growing CCOP staff with a history of excellent retention of personnel and with successful performance over the 19 year history of the NCI CCOP program. The system enjoys a large network of primary care practices, with all practices and all physicians (including specialists) linked by a state-of-art electronic medical record (EPIC-Care), and a large cancer patient population (over 2000 new analytic cases/year). The addition of new System C.E.O. Dr. Glenn Steele, a prominent academic surgical oncologist and researcher, has given new emphasis to the institutional commitment to growing cancer research. The System has been reorganized into Service Lines, which has greatly aided the Cancer Service Line, Geisinger Cancer Institute, in recruiting and building in all three major hub sites. Clinical trial performance is enhanced by a new computerized clinical protocol management system (Protonet), a System-wide cancer registry that includes all outpatient as well as all hospital sites, and the computerized medical record with interlocked laboratory, radiology, demographics, appointments and on-line digital images. Recruiting participants onto prevention trials has been helped by direct recruiting by Geisinger's HMO, which is clinical research friendly, seeing such activities as part of its primary health promotion mission. This proposal retains NCCTG as the primary research base, ECOG as a secondary base, COG as our children's base, and GOG (MD Anderson affiliation) as a separate gynecologic base.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA035448-20
Application #
6618633
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J1))
Program Officer
O'Mara, Ann M
Project Start
1998-07-01
Project End
2008-05-31
Budget Start
2003-06-01
Budget End
2004-05-31
Support Year
20
Fiscal Year
2003
Total Cost
$582,640
Indirect Cost
Name
Geisinger Medical Center
Department
Type
DUNS #
City
Danville
State
PA
Country
United States
Zip Code
17822
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Hubbard, Joleen M; Mahoney, Michelle R; Loui, William S et al. (2017) Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 12:201-209
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27
Loprinzi, Charles L; Qin, Rui; Dakhil, Shaker R et al. (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997-1005
Kottschade, Lisa A; Suman, Vera J; Perez, Domingo G et al. (2013) A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer 119:586-92
Patel, Krishna; Foster, Nathan R; Farrell, Ann et al. (2013) Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature. J Cancer Educ 28:770-6
Barton, Debra L; Burger, Kelli; Novotny, Paul J et al. (2013) The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 21:1185-92

Showing the most recent 10 out of 115 publications